Suppliers and packagers for generic pharmaceutical drug: NILOTINIB HYDROCHLORIDE

NILOTINIB HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	NILOTINIB HYDROCHLORIDE	nilotinib hydrochloride	CAPSULE;ORAL	203640	ANDA	Apotex Corp.	60505-3801-0	2 BLISTER PACK in 1 CARTON (60505-3801-0) / 14 CAPSULE in 1 BLISTER PACK	2025-05-23
Apotex	NILOTINIB HYDROCHLORIDE	nilotinib hydrochloride	CAPSULE;ORAL	203640	ANDA	Apotex Corp.	60505-3801-2	4 CARTON in 1 CARTON (60505-3801-2) / 2 BLISTER PACK in 1 CARTON (60505-3801-3) / 14 CAPSULE in 1 BLISTER PACK	2025-05-23
Apotex	NILOTINIB HYDROCHLORIDE	nilotinib hydrochloride	CAPSULE;ORAL	203640	ANDA	Apotex Corp.	60505-3802-0	2 BLISTER PACK in 1 CARTON (60505-3802-0) / 14 CAPSULE in 1 BLISTER PACK	2025-05-23

Nilotinib Hydrochloride Suppliers

Last updated: February 19, 2026

This analysis identifies key suppliers for Nilotinib Hydrochloride, a tyrosine kinase inhibitor used in treating chronic myeloid leukemia. The report details manufacturing capabilities, regulatory standing, and geographical distribution of active pharmaceutical ingredient (API) manufacturers and finished dosage form (FDF) producers.

Who Manufactures Nilotinib Hydrochloride API?

Several manufacturers globally produce Nilotinib Hydrochloride API, with significant concentrations in India and China. These suppliers cater to both generic and branded drug manufacturers, operating under varying levels of regulatory oversight.

• Key API Manufacturers:

  • Eutectic India Limited (now part of Cipla): A prominent Indian pharmaceutical company with established API manufacturing capabilities.
  • Lupin Limited: Another major Indian pharmaceutical firm known for its broad API portfolio and international regulatory compliance.
  • Dr. Reddy's Laboratories: A multinational pharmaceutical company headquartered in India, with significant API production capacity.
  • Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company by market capitalization, with extensive API manufacturing facilities.
  • Jiangsu Hengrui Medicine Co., Ltd.: A leading Chinese pharmaceutical company with a strong focus on R&D and API production.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.: A Chinese pharmaceutical manufacturer with a significant global presence in API supply.
  • Divi's Laboratories: An Indian API manufacturer recognized for its large-scale production and quality standards.

• Regulatory Status of API Suppliers:

  • Many of these suppliers hold accreditations from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This is crucial for market access in regulated territories. For example, Dr. Reddy's Laboratories has multiple FDA-approved facilities.
  • Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are common among European and Indian API suppliers, indicating compliance with European standards.
  • Chinese API manufacturers are increasingly aligning with international quality standards to compete in global markets.

• Production Capacity and Scale:

  • Leading suppliers like Divi's Laboratories and Huahai Pharmaceutical operate large-scale manufacturing plants, capable of producing metric tons of API annually. This scale is necessary to meet the demand for a widely prescribed drug.
  • Capacity is often measured in terms of reactor volumes and total output per year, with major players reporting annual capacities in the hundreds of metric tons for key APIs.

• Intellectual Property Considerations:

  • The patent landscape for Nilotinib Hydrochloride has been a significant factor. The original patent for Nilotinib (Tasigna) was held by Novartis AG.
  • Generic manufacturers typically enter the market after patent expiry or through licensing agreements. The expiry dates of key patents influence the entry of new API suppliers and the pricing of the generic API. For instance, the U.S. patent for Nilotinib expired in late 2022, opening the market for generic competition.

Which Companies Produce Nilotinib Hydrochloride Finished Dosage Forms (FDFs)?

FDF production involves formulating the API into the final drug product, such as capsules. This segment is characterized by both originator companies and a growing number of generic manufacturers.

• Originator Company:

  • Novartis AG: The originator of Nilotinib, marketing it under the brand name Tasigna®. Novartis maintains stringent quality control and supply chain management for its branded product.

• Key Generic FDF Manufacturers:

  • Teva Pharmaceutical Industries Ltd.: A leading global generic pharmaceutical company with a presence in many regulated markets.
  • Mylan N.V. (now part of Viatris): Another significant player in the generic drug market, known for its broad product portfolio.
  • Torrent Pharmaceuticals Ltd.: An Indian multinational pharmaceutical company that has established a strong presence in the generic oncology segment.
  • Aurobindo Pharma Ltd.: A vertically integrated Indian pharmaceutical company manufacturing both APIs and FDFs.
  • Hetero Drugs Ltd.: One of India's largest privately held pharmaceutical companies, with substantial FDF manufacturing capabilities.
  • Sun Pharmaceutical Industries Ltd.: In addition to API, Sun Pharma also manufactures finished dosage forms.

• Regulatory Approvals for FDFs:

  • Generic FDF manufacturers require marketing authorizations from national regulatory agencies such as the FDA (for the U.S. market), EMA (for the European Union), and others for specific countries.
  • Abbreviated New Drug Applications (ANDAs) are submitted to the FDA for generic drug approval, demonstrating bioequivalence to the reference listed drug (Tasigna®).
  • Key markets for generic Nilotinib Hydrochloride FDFs include the United States, European Union member states, Canada, Australia, and India.

• Formulations and Strengths:

  • Nilotinib Hydrochloride is typically available in capsule form.
  • Common strengths include 150 mg and 300 mg capsules.
  • Manufacturers must demonstrate precise dosage accuracy and stability of the finished product.

• Market Entry Dynamics:

  • Generic entry is triggered by patent expiries and the successful approval of ANDAs. The timing of these events dictates market competition and pricing.
  • First-to-file (FTF) exclusivity can provide a significant market advantage for the first generic company to receive FDA approval.

What is the Geographical Distribution of Nilotinib Hydrochloride Supply?

The supply chain for Nilotinib Hydrochloride is global, with key hubs for API manufacturing in Asia and FDF manufacturing and distribution spread across North America, Europe, and Asia.

• API Manufacturing Hubs:

  • India: Dominant supplier of generic APIs, with a high concentration of manufacturers holding international regulatory approvals. Companies like Cipla, Lupin, Dr. Reddy's, Sun Pharma, and Divi's Laboratories have a strong presence.
  • China: A growing source of APIs, with companies like Jiangsu Hengrui Medicine and Zhejiang Huahai Pharmaceutical increasing their global market share. Regulatory compliance is a key differentiator for Chinese suppliers.
  • Europe: Some specialized API manufacturers in Europe may produce niche intermediates or the final API, often focusing on high-purity or custom synthesis. However, the bulk of generic API production is concentrated in Asia.

• FDF Manufacturing and Distribution Centers:

  • North America (United States and Canada): Major markets for both branded and generic Nilotinib Hydrochloride. FDF manufacturing is conducted by both global generic players and, in some cases, by local subsidiaries of multinational companies.
  • Europe: A significant market with stringent regulatory requirements. FDF production is carried out by established generic companies and local entities serving specific EU member states.
  • Asia (India, China, Southeast Asia): While a source of API, these regions are also increasingly becoming significant markets for generic FDFs, driven by growing healthcare access and demand.
  • Other Regions: Latin America, Africa, and the Middle East represent emerging markets where generic Nilotinib Hydrochloride is gaining traction.

• Supply Chain Risks and Mitigation:

  • Geopolitical Stability: Reliance on specific regions for API manufacturing can introduce risks related to trade policies, political instability, and natural disasters. Diversification of API suppliers is a key mitigation strategy.
  • Regulatory Changes: Evolving regulatory requirements in different countries can impact market access and necessitate ongoing compliance efforts.
  • Quality Control: Ensuring consistent quality across the global supply chain, from API to FDF, is paramount. Robust quality management systems and audits are essential.
  • Logistics and Transportation: The secure and timely transport of temperature-sensitive pharmaceutical products globally requires specialized logistics networks.

How Does Patent Expiry Impact Supplier Landscape?

Patent expiry is a primary driver for the diversification of the Nilotinib Hydrochloride supplier landscape, leading to increased competition and market access for generic products.

• Original Patent Holder:

  • Novartis AG held the primary patents for Nilotinib. The expiry of these core patents allowed for the introduction of generic versions.
  • The U.S. patent for Nilotinib expired in late 2022, marking a significant opportunity for generic manufacturers.
  • European patent expiries have also followed, varying by country due to different patent lifecycles and legal challenges.

• Generic Market Entry:

  • Upon patent expiry, companies that have successfully developed and received approval for generic versions can launch their products.
  • This typically leads to a rapid increase in the number of API and FDF suppliers in the market.
  • The first generic entrant often captures a substantial market share due to exclusivity periods granted by some regulatory bodies.

• Impact on API Suppliers:

  • Patent expiry increases demand for generic API manufacturers.
  • API prices tend to decrease as competition intensifies among suppliers.
  • API suppliers must maintain high-quality standards and cost-competitiveness to secure contracts with FDF manufacturers.
  • The availability of multiple API sources reduces the risk for FDF manufacturers of a single supplier disruption.

• Impact on FDF Manufacturers:

  • Generic FDF manufacturers benefit from the availability of affordable generic APIs.
  • They face increased competition from other generic players, driving down FDF prices.
  • Market access is contingent on obtaining regulatory approval for their generic products in target countries.
  • Success depends on efficient manufacturing, robust distribution networks, and effective marketing strategies.

• Therapeutic Equivalency:

  • For generic drugs to be approved, they must be proven bioequivalent to the reference listed drug (Tasigna®). This is assessed through clinical trials and rigorous quality control measures by regulatory agencies like the FDA and EMA.
  • This ensures that generic Nilotinib Hydrochloride products offer the same safety and efficacy profile as the originator product.

What Regulatory Hurdles Do Suppliers Face?

Suppliers of Nilotinib Hydrochloride, whether API or FDF, must navigate a complex web of international regulatory requirements to ensure product safety, efficacy, and market access.

• API Manufacturing Regulations:

  • Good Manufacturing Practices (GMP): Adherence to current GMP (cGMP) is mandatory. Regulatory agencies, including the FDA and EMA, conduct regular inspections of manufacturing facilities to ensure compliance.
  • Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities (e.g., FDA in the U.S.). These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. FDF manufacturers reference these DMFs in their drug applications.
  • Certificates of Suitability (CEP): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required, demonstrating that the API complies with European Pharmacopoeia monographs.
  • Impurity Profiling: Strict control and characterization of impurities, including genotoxic impurities, are critical. Regulatory bodies set stringent limits for these substances.

• FDF Manufacturing Regulations:

  • Marketing Authorization Applications (MAA) / New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDA): FDF manufacturers must obtain approval to market their products. For generics, ANDAs are submitted to the FDA, proving bioequivalence to the reference drug.
  • GMP Compliance: FDF manufacturing facilities are also subject to cGMP regulations, covering all aspects of production, packaging, labeling, and quality control.
  • Stability Studies: Manufacturers must conduct comprehensive stability studies to demonstrate that the finished product remains safe and effective throughout its shelf life.
  • Labeling and Packaging: Compliance with specific national requirements for drug labeling and packaging, including patient information leaflets, is mandatory.

• International Variations:

  • Regulatory requirements can vary significantly between countries. Suppliers looking to enter multiple markets must often tailor their compliance strategies to meet diverse national standards.
  • Emerging markets may have less developed regulatory frameworks but often require adherence to WHO GMP guidelines.

• Post-Approval Compliance:

  • Regulatory compliance is an ongoing process. Suppliers must report changes in manufacturing processes, quality control, or address any post-market safety issues through pharmacovigilance systems.
  • Periodic re-inspections by regulatory authorities are common.

Key Takeaways

The supply of Nilotinib Hydrochloride is a global ecosystem comprising established API manufacturers, primarily in India and China, and a diverse range of generic FDF producers. Patent expiries have been instrumental in opening the market to generic competition, leading to increased supplier diversity and price competitiveness. Navigating rigorous regulatory landscapes, including GMP compliance and the filing of detailed drug master files, is paramount for all suppliers to ensure market access in key regions like North America and Europe. The geographical distribution of manufacturing, with its inherent risks, necessitates robust supply chain management and quality control to guarantee the availability of safe and effective Nilotinib Hydrochloride products worldwide.

FAQs

1. What is the primary difference in regulatory requirements for API suppliers versus FDF suppliers? API suppliers must file Drug Master Files (DMFs) detailing their manufacturing process and quality control, which FDF applicants reference. FDF suppliers, in turn, must demonstrate bioequivalence of their final product to the reference drug and obtain marketing authorization. Both are subject to stringent Good Manufacturing Practices (GMP) inspections.

2. How can a new generic FDF manufacturer ensure a stable supply of Nilotinib Hydrochloride API? New entrants should identify multiple API suppliers with strong regulatory track records (e.g., FDA-approved facilities, CEPs) and consider dual-sourcing or multi-sourcing strategies to mitigate supply chain risks. Establishing strong contractual agreements that include quality and delivery guarantees is also crucial.

3. What are the potential implications of geopolitical instability on the Nilotinib Hydrochloride supply chain? Geopolitical instability can lead to trade disputes, sanctions, or disruptions in shipping and logistics, potentially affecting the availability and cost of both API and FDF. This risk can be mitigated by diversifying manufacturing locations for both API and FDF, where feasible, and maintaining strategic inventory levels.

4. Beyond patent expiry, what other factors influence the entry of new suppliers for Nilotinib Hydrochloride? Other factors include significant investment in manufacturing capacity, the ability to develop cost-effective and high-quality manufacturing processes, successful navigation of complex regulatory approval pathways in target markets, and the existence of established distribution networks.

5. How is bioequivalence established for generic Nilotinib Hydrochloride products? Bioequivalence is established through clinical studies where pharmacokinetic parameters (such as the rate and extent of drug absorption) of the generic product are compared to those of the reference listed drug (Tasigna®) in a controlled study population, typically healthy volunteers. Regulatory agencies like the FDA and EMA review these data to ensure the generic product performs the same way as the branded drug in the body.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files-dmfs

[2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia-cep

[3] Novartis AG. (n.d.). Tasigna® (nilotinib hydrochloride). Retrieved from https://www.novartis.com/our-portfolio/products/tasigna

[4] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/types-new-drug-applications/abbreviated-new-drug-applications-andas

[5] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products . Retrieved from https://www.who.int/teams/regulation-prequalification/standards-and-setting/good-manufacturing-practices